GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.

Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.

This year, revolutionary anti-obesity drugs Wegovy and Ozempic (manufactured by Danish drugmaker Novo Nordisk), and Eli Lilly ...

Millions of Americans are estimated to suffer from obstructive sleep apnea, a sleep disorder. Eli Lilly and Ozempic and Wegovy-maker Novo Nordisk (NVO) are testing their weight-loss drugs ...

We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Announcing the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final health ...

Announcement of the 15 medicines chosen for the second round of negotiations was one of the Biden administration’s final ...

Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...